SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around a shared mission and positive outlook, reflected in their motto 'We're All Gonna Make It.' Discussions highlight the token's strong community, resilient liquidity, and potential for significant growth within the Solana ecosystem, with some suggesting it's 'WAGMI szn'.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as discussions revolve around a potential deal with Larvotto Resources (LRV) and speculation about U.S. government involvement to secure antimony supply outside of China. Community members are debating the deal's implications, potential government stakes, and the stock's future value amidst volatile market conditions. Some investors believe UAMY is "China-proof" and undervalued, while others express concerns about market manipulation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The QQQ is trending amid ongoing U.S.-China trade discussions and anticipation of upcoming big tech earnings and a potential rate cut. Community sentiment appears cautiously optimistic, though some express concern that the market's gains are based on speculation rather than concrete progress, creating a potential bubble. Discussions also involve potential impacts from international events and domestic economic factors.

WorldFinancial

WorldFinancial (WLFI) is trending as traders discuss its potential to break through resistance and rally. Community members are highlighting recent breakouts and urging others to load up, with some anticipating a significant surge. The coin is also associated with wider bullish sentiment surrounding $WAGMI, $SOL, and $BTC.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a bullish sentiment, using the phrase "WAGMI" (We're All Gonna Make It). Discussions range from potential price targets to new projects and meme coins building on the Solana network. Traders are closely watching key resistance levels, anticipating a breakout.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending following news of a $150 million registered direct offering, with community members debating the implications of the raise and new institutional investors. Some view the offering as a sign of growth and confidence in the company's AI-driven photonics technology, while others express concerns about potential dilution and short-term volatility. Bullish sentiment remains strong with continued discussion around potential partnerships and future impact of POET's optical interposer technology in the AI and data center space.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with many expecting a positive report and discussing potential price movement following the release. Community members are also eyeing potential tailwinds like rate cuts and the possibility of crypto trading on the platform soon. Overall, there's considerable buzz around SoFi's growth prospects and potential for a valuation reset.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending upward as traders react to U.S.-China trade deal framework discussions and anticipation of a finalized agreement. Bullish sentiment is fueled by expectations of paused tariffs and increased soybean purchases, with some traders eyeing new all-time highs. The community is also closely watching for potential impacts from upcoming earnings reports and the Fed meeting.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending as investors discuss its potential breakout, with many highlighting significant call option activity and a possible short squeeze. Community members are analyzing technical setups and anticipating a move toward higher price targets, while also weighing the impact of upcoming earnings and lockup expirations. Bullish sentiment is fueled by news of potential integration with major financial institutions and the increasing adoption of stablecoins.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amid discussions around rare earth minerals, potential government contracts, and its relationship with both Australia and China. Community members are actively debating the impact of potential trade deals, the company's financial health, and technical indicators, with some highlighting unusual options activity. The stock's volatility and potential for both short-term pullbacks and long-term gains are also key points of discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Ligand Pharmaceuticals and Pelthos Therapeutics rose on Thursday after the commercial launch of Zelsuvmi (berdazimer) topical gel, developed under their partnership,&nbsp;to treat a common viral skin infection.<a href="https://stocktwits.com/symbol/PTHS">Pelthos Therapeutics</a> surged 60.8% to close at $10.01 on Thursday, while&nbsp;<a href="https://stocktwits.com/symbol/LGND">Ligand Pharmaceuticals</a> gained 2.1%.The launch triggered a $5 million milestone payment to Ligand under the companies’ license agreement. Under the terms of the licensing deal, Ligand is also entitled to a 13% royalty on worldwide sales of Zelsuvmi and up to $5 million in additional commercial milestones.Ligand also holds a 56% equity stake in Pelthos following the completion of a merger between Pelthos and Channel Therapeutics on July 2.Pelthos announced the merger earlier this month, in which CHRO Merger Sub, a wholly owned subsidiary of Channel, merged with LNHC, a wholly owned subsidiary of Ligand.&nbsp;LNHC survived as a subsidiary of Channel, and the combined company is now operating under the Pelthos Therapeutics name. Concurrent with the merger, Pelthos raised $50.1 million in a private placement led by Murchinson.&nbsp;The investment included new equity as well as the cancellation of $18.8 million in previously advanced bridge capital used to support the commercial launch of Zelsuvmi.Zelsuvmi is a nitric oxide-releasing topical gel approved by the U.S. Food and Drug Administration in 2024 for the treatment of molluscum contagiosum,&nbsp;sometimes known commonly as “water warts”, in patients aged one year and older.&nbsp;It is the first prescription medication approved for at-home application by patients, parents, or caregivers. The product was developed using the nitric oxide-based Nitricil platform, now owned by Ligand.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment for both Ligand Pharmaceuticals and Pelthos Therapeutics was ‘bullish’, with ‘high’ message volume for Ligand and ‘extremely high’ activity for Pelthos.Ligand’s stock has gained 15.3%so far in 2025, while Pelthos has surged 266.3% over the same period.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-canada-with-35-tariff-by-august-mulls-blanket-rates-for-others/ch8TD9uR5l4">Trump Threatens Canada With 35% Tariff By August, Mulls Blanket 15-20% Rates For Other Countries</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ligand Pharmaceuticals (LGND) and Pelthos Therapeutics (PTHS) commercially launched Zelsuvmi (berdazimer) topical gel (Photo credit: Getty Images)

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Equity

Shares of Channel Therapeutics Corporation (CHRO) rocketed 61% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.ligand.com/news-and-events/press-releases/news-details/2025/Ligand-Subsidiary-Pelthos-Therapeutics-to-Combine-with-Channel-Therapeutics/default.aspx">entered</a> into a definitive merger agreement with biopharmaceutical firm Ligand Pharmaceuticals Incorporated (LGND).Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc., will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.Channel will acquire 100% of the issued and outstanding equity interests of Pelthos Therapeutics and LNHC, and will change its name to Pelthos Therapeutics Inc.Ligand has agreed to invest $18 million in the combined company, while a group of strategic investors led by Murchinson has agreed to invest $32 million.The transaction is expected to close in the summer of 2025.Once the transaction is completed, the combined company will trade on the NYSE American exchange under the ticker PTHS.Channel, a non-opioid pain treatment therapeutics provider, stated that the combined company will initially focus on accelerating the commercialization of Pelthos’ FDA-approved Zelsuvmi topical gel for the treatment of Molluscum contagiosum infections in adults and pediatric patients aged one year and older.Molluscum contagiosum is a poxvirus, afflicting an estimated 16.7 million people in the United States.Ligand will be entitled to a 13% royalty on worldwide sales of Zelsuvmi, the company said.The combined company will also retain Channel’s existing development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks, it added.Channel CEO Frank Knuettel II said that the company performed “extensive due diligence” on the Zelsuvmi market opportunity.“Strategically, it (the merger) provides the potential for near-term revenue generation from an FDA-approved drug, the opportunity to advance Channel’s existing NaV 1.7 programs, and expanded capitalization from strong, long-standing investors,” he said.“This transaction presents a compelling opportunity to launch a commercial-ready product, with significant financial backing from Murchinson, that has the potential to deliver both near and long-term value to our shareholders,” said Ligand CEO Todd Davis.On Stocktwits, retail sentiment around Ligand jumped further into the ‘extremely bullish’ territory over the past 24 hours coupled with a surge in message volume from ‘low’ to ‘extremely high’<figure class="image"><img style="aspect-ratio:648/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_08_AM_png_52226d4e3f.webp" alt="LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits" width="648" height="147"><figcaption>LGND's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/LGND">LGND stock</a> is down by about 3% this year but up by over 33% over the past 12 months.Retail sentiment around Channel, meanwhile, jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_10_29_44_AM_png_bccf41e1ea.webp" alt="CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits"><figcaption>CHRO's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CHRO">CHRO stock</a> is up by about 172% year-to-date but down by nearly 1.5% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/lockheed-martin-stock-drops-after-cfo-jay-malave-steps-down-just-days-before-q1-earnings/chQEM9RRbfN">Lockheed Martin Stock Drops After CFO Jay Malave Steps Down Just Days Before Q1 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial markets on...

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Oppenheimer 35th Annual...

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza, and...

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare...

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update...

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor and Analyst Day in Boston on Tuesday, December 10, 2024 from 10:30 a.m. to 12:00 p.m. Eastern Time...

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7...

Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know

Latest Ratings for LGND
 DateFirmActionFromTo Feb 2022BenchmarkMaintainsBuy Feb 2022BarclaysMaintainsOverweight Sep 2021BarclaysMaintainsOverweight
 View More Analyst Ratings for LGND...

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LGND News

LGNDLigand Pharmaceuticals, Inc. - Ordinary Shares - Class B